Flibanserin Nears Approval, But Much Work Remains
The Food and Drug Administration (FDA) Advisory Committee has made history for women by recommending approval of Sprout Pharmaceuticals’ twice-rejected female libido drug Flibanserin.
Aimed at pre-menopausal women, Flibanserin is the potential first-ever medical treatment option for hypoactive sexual desire disorder (HSDD). Currently, there are 16 million American women living without a single FDA-approved medical treatment option for HSDD.
“This was an important step taken by the advisory committee in consideration of the scientific evidence presented to them and the need that women with HSDD have for some form of treatment,” said Phyllis Greenberger, MSW, President and CEO, of the Society for Women’s Health Research (SWHR). The FDA will issue its final decision on Flibanserin in August.
To learn more about SWHR, the thought leader in transforming women’s health research, visit www.swhr.org.
The Food and Drug Administration (FDA) Advisory Committee has made history for women by recommending approval of Sprout Pharmaceuticals’ twice-rejected female libido drug Flibanserin.
Aimed at pre-menopausal women, Flibanserin is the potential first-ever medical treatment option for hypoactive sexual desire disorder (HSDD). Currently, there are 16 million American women living without a single FDA-approved medical treatment option for HSDD.
“This was an important step taken by the advisory committee in consideration of the scientific evidence presented to them and the need that women with HSDD have for some form of treatment,” said Phyllis Greenberger, MSW, President and CEO, of the Society for Women’s Health Research (SWHR). The FDA will issue its final decision on Flibanserin in August.
To learn more about SWHR, the thought leader in transforming women’s health research, visit www.swhr.org.